Adaptimmune Therapeutics plc

The US Food and Drug Administration takes a “more pragmatic” approach to cell and gene therapy development, which provides companies with a “less stringent pathway” to show that their product has pote

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Financing of UK biotech companies nearly doubled in 2024 compared with the year before, with £3.5bn ($4.34bn) being raised to support new and existing companies. That represented a 94% increase in tot

Kronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger